1. ASS1 Overexpression: A Hallmark of Sonic Hedgehog Hepatocellular Adenomas; Recommendations for Clinical Practice
- Author
-
Sala, M., Gonzales, D., Leste-Lasserre, T., Dugot-Senant, N., Paradis, V., Di Tommaso, S., Dupuy, J.W., Pitard, V., Dourthe, C., Sciarra, A., Sempoux, C., Ferrell, L.D., Clouston, A.D., Miller, G., Yeh, M.M., Thung, S., Gouw, ASH, Quaglia, A., Han, J., Huan, J., Fan, C., Crawford, J., Nakanuma, Y., Harada, K., le Bail, B., Castain, C., Frulio, N., Trillaud, H., Possenti, L., Blanc, J.F., Chiche, L., Laurent, C., Balabaud, C., Bioulac-Sage, P., Raymond, A.A., Saltel, F., and Groningen Institute for Organ Transplantation (GIOT)
- Subjects
PCR ,MARKERS ,MOLECULAR CLASSIFICATION ,RISK-FACTORS ,MANAGEMENT ,lcsh:Diseases of the digestive system. Gastroenterology ,Original Article ,Original Articles ,lcsh:RC799-869 ,TRANSFORMATION - Abstract
Until recently, 10% of hepatocellular adenomas (HCAs) remained unclassified (UHCA). Among the UHCAs, the sonic hedgehog HCA (shHCA) was defined by focal deletions that fuse the promoter of Inhibin beta E chain with GLI1. Prostaglandin D2 synthase was proposed as immunomarker. In parallel, our previous work using proteomic analysis showed that most UHCAs constitute a homogeneous subtype associated with overexpression of argininosuccinate synthase (ASS1). To clarify the use of ASS1 in the HCA classification and avoid misinterpretations of the immunohistochemical staining, the aims of this work were to study (1) the link between shHCA and ASS1 overexpression and (2) the clinical relevance of ASS1 overexpression for diagnosis. Molecular, proteomic, and immunohistochemical analyses were performed in UHCA cases of the Bordeaux series. The clinico‐pathological features, including ASS1 immunohistochemical labeling, were analyzed on a large international series of 67 cases. ASS1 overexpression and the shHCA subgroup were superimposed in 15 cases studied by molecular analysis, establishing ASS1 overexpression as a hallmark of shHCA. Moreover, the ASS1 immunomarker was better than prostaglandin D2 synthase and only found positive in 7 of 22 shHCAs. Of the 67 UHCA cases, 58 (85.3%) overexpressed ASS1, four cases were ASS1 negative, and in five cases ASS1 was noncontributory. Proteomic analysis performed in the case of doubtful interpretation of ASS1 overexpression, especially on biopsies, can be a support to interpret such cases. ASS1 overexpression is a specific hallmark of shHCA known to be at high risk of bleeding. Therefore, ASS1 is an additional tool for HCA classification and clinical diagnosis., ShHCA is a new HCA subgroup with a high risk of bleeding with PTGDS and ASS1 proposed as immunomarkers, with conflicting results and interpretations in the literature. By molecular, proteomic, and immunohistochemistry analyses, we established that ASS1 overexpression was a specific hallmark of shHCA. Having shown that PTGDS was not a good marker, we demonstrated, using a large cohort of UHCAs, the sensitivity of ASS1 immunomarker and its clinical relevance. Therefore, ASS1 is an additional tool for HCA classification, clinical diagnosis of shHCA, and appropriate management.
- Published
- 2019